{"id":66238,"date":"2026-05-25T23:04:18","date_gmt":"2026-05-25T15:04:18","guid":{"rendered":"https:\/\/flcube.com\/?p=66238"},"modified":"2026-05-25T23:04:19","modified_gmt":"2026-05-25T15:04:19","slug":"regenerons-otarmeni-gene-therapy-accepted-for-ema-accelerated-review-as-first-potential-treatment-for-otof-related-hearing-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66238","title":{"rendered":"Regeneron&#8217;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Regeneron Pharmaceuticals, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>)<\/strong> announced that the <strong>European Medicines Agency (EMA)<\/strong> has accepted for <strong>accelerated review<\/strong> the <strong>Marketing Authorization Application (MAA)<\/strong> for <strong>Otarmeni (lunsotogene parvec)<\/strong>, an adeno-associated virus (AAV) vector-based gene therapy designed to treat <strong>hearing loss caused by biallelic variants in the OTOF gene<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-status-amp-development-milestone\" class=\"wp-block-heading\">Regulatory Status &amp; Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)<\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td>Otarmeni (lunsotogene parvec)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>European Medicines Agency (EMA)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Accelerated review accepted<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Marketing Authorization Application (MAA)<\/td><\/tr><tr><td><strong>Current Approval Status<\/strong><\/td><td>Already approved in the United States<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>EMA Orphan Drug Designation previously granted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-unmet-medical-need\" class=\"wp-block-heading\">Disease Background &amp; Unmet Medical Need<\/h2>\n\n\n\n<h3 id=\"h-otof-related-hearing-loss-profile\" class=\"wp-block-heading\">OTOF-Related Hearing Loss Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Classification:<\/strong> Ultra-rare genetic disorder<\/li>\n\n\n\n<li><strong>EU Incidence:<\/strong> Approximately <strong>46 newborns per year<\/strong> across the European Union<\/li>\n\n\n\n<li><strong>Pathophysiology:<\/strong> Biallelic variants in the <strong>OTOF gene<\/strong> lead to absence of functional <strong>otoferlin protein<\/strong><\/li>\n\n\n\n<li><strong>Anatomical Integrity:<\/strong> All ear structures remain intact; defect is purely at the molecular signaling level<\/li>\n\n\n\n<li><strong>Functional Impact:<\/strong> Otoferlin protein is essential for signal transmission between inner ear sensory cells and the auditory nerve<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-current-treatment-landscape\" class=\"wp-block-heading\">Current Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Standard of Care:<\/strong> Hearing aids and cochlear implants (symptomatic management only)<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> No disease-modifying treatments exist<\/li>\n\n\n\n<li><strong>Clinical Urgency:<\/strong> Early intervention critical for speech and language development in affected infants<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-gene-therapy-mechanism-amp-innovation\" class=\"wp-block-heading\">Gene Therapy Mechanism &amp; Innovation<\/h2>\n\n\n\n<h3 id=\"h-molecular-approach\" class=\"wp-block-heading\">Molecular Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vector Platform:<\/strong> Adeno-associated virus (AAV) vector-based delivery system<\/li>\n\n\n\n<li><strong>Therapeutic Strategy:<\/strong> Single-dose gene replacement therapy delivering functional OTOF gene<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Patients with confirmed biallelic OTOF variants<\/li>\n\n\n\n<li><strong>Potential Outcome:<\/strong> Restoration of otoferlin protein expression and auditory signal transmission<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-significance\" class=\"wp-block-heading\">Clinical Significance<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If approved, Otarmeni would become the <strong>first gene therapy for OTOF-related hearing loss<\/strong> in the European Union, representing a paradigm shift from symptomatic management to potential cure. The therapy addresses the root cause of the disease rather than compensating for hearing loss through external devices.<\/p>\n\n\n\n<h2 id=\"h-market-implications-amp-commercial-strategy\" class=\"wp-block-heading\">Market Implications &amp; Commercial Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Despite affecting only <strong>46 newborns annually in the EU<\/strong>, OTOF-related hearing loss represents a high-value ultra-orphan indication due to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transformative Clinical Benefit:<\/strong> Potential to restore natural hearing function<\/li>\n\n\n\n<li><strong>Premium Pricing Potential:<\/strong> Gene therapies for ultra-rare diseases typically command seven-figure price tags<\/li>\n\n\n\n<li><strong>Regulatory Incentives:<\/strong> Orphan drug designation provides market exclusivity and development support<\/li>\n\n\n\n<li><strong>Precedent Setting:<\/strong> Success could pave the way for additional genetic hearing loss indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Regeneron&#8217;s accelerated review acceptance reflects the EMA&#8217;s recognition of the substantial unmet medical need and the therapy&#8217;s potential to address a condition with no existing disease-modifying treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s established expertise in AAV-based gene therapies, combined with its successful US approval, positions Regeneron well to navigate the European regulatory pathway and establish commercial infrastructure for this specialized ultra-orphan product.<\/p>\n\n\n\n<h2 id=\"h-broader-industry-impact\" class=\"wp-block-heading\">Broader Industry Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Otarmeni&#8217;s development represents a significant advancement in the field of genetic hearing loss therapeutics, demonstrating the feasibility of gene replacement approaches for sensory disorders. Success in this indication could catalyze investment in other genetic forms of hearing loss affecting larger patient populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The therapy also highlights the growing trend of <strong>ultra-orphan gene therapies<\/strong> targeting conditions with extremely small patient populations but offering transformative clinical benefits, supported by favorable regulatory frameworks and premium reimbursement models.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including final regulatory decisions, clinical trial outcomes, pricing negotiations, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[66,38,1166,1426],"class_list":["post-66238","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-gene-therapy","tag-market-approval-filings","tag-nasdaq-regn","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron&#039;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66238\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron&#039;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss\" \/>\n<meta property=\"og:description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66238\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T15:04:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T15:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron&#8217;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss\",\"datePublished\":\"2026-05-25T15:04:18+00:00\",\"dateModified\":\"2026-05-25T15:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2505.webp\",\"keywords\":[\"Gene therapy\",\"Market approval filings\",\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66238#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66238\",\"name\":\"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2505.webp\",\"datePublished\":\"2026-05-25T15:04:18+00:00\",\"dateModified\":\"2026-05-25T15:04:19+00:00\",\"description\":\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66238\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66238#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron&#8217;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss - Insight, China&#039;s Pharmaceutical Industry","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66238","og_locale":"en_US","og_type":"article","og_title":"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss","og_description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.","og_url":"https:\/\/flcube.com\/?p=66238","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T15:04:18+00:00","article_modified_time":"2026-05-25T15:04:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66238#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66238"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron&#8217;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss","datePublished":"2026-05-25T15:04:18+00:00","dateModified":"2026-05-25T15:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66238"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66238#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","keywords":["Gene therapy","Market approval filings","NASDAQ: REGN","Regeneron Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66238#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66238","url":"https:\/\/flcube.com\/?p=66238","name":"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66238#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66238#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","datePublished":"2026-05-25T15:04:18+00:00","dateModified":"2026-05-25T15:04:19+00:00","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for accelerated review the Marketing Authorization Application (MAA) for Otarmeni (lunsotogene parvec), an adeno-associated virus (AAV) vector-based gene therapy designed to treat hearing loss caused by biallelic variants in the OTOF gene.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66238#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66238"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66238#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","width":1080,"height":608,"caption":"Regeneron's Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66238#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron&#8217;s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66238"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66238\/revisions"}],"predecessor-version":[{"id":66241,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66238\/revisions\/66241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66239"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}